Faculty of Medicine教員紹介:三好 潤

氏名 三好 潤
ミヨシ ジュン MIYOSHI, Jun
職位講師
所属教室消化器内科学
専攻・専門分野
 (大学院)
内科系専攻 内科学分野(消化器内科学)
専門分野炎症性腸疾患、腸内微生物叢、消化管免疫
研究テーマ炎症性腸疾患の病態生理、宿主免疫機構の発達における腸内微生物叢の役割、炎症性腸疾患の疾患活動性モニタリングおよび治療効果予測
略歴2006年 慶應義塾大学医学部卒業
2012年 慶應義塾大学大学院医学研究科博士課程修了
2012年 東京歯科大学市川総合病院消化器内科助教
2014年 米国シカゴ大学消化器科博士研究員
2019年 杏林大学医学部消化器内科学学内講師 
2022年 杏林大学医学部消化器内科学講師
所有する学位博士(医学)
指導医・専門医・認定医、その他の資格等日本内科学会総合内科専門医、日本消化器病学会消化器病専門医、日本消化器内視鏡学会専門医、日本消化管学会胃腸科専門医
論文・著書等を含む主要研究業績 (英語論文: 最近5年間)
Frazier K, Kambal A, Zale EA, Pierre JF, Hubert N, Miyoshi S, Miyoshi J, Ringus DL, Harris D, Yang K, Carroll K, Hermanson JB, Chlystek JS, Overmyer KA, Cham CM, Musch MW, Coon JJ, Chang EB, Leone VA. High-fat diet disrupts REG3γ and gut microbial rhythms promoting metabolic dysfunction. Cell Host Microbe. 2022:S1931-3128(22)00160-3. Epub ahead of print.
Miyoshi J, Ozaki R, Yonezawa H, Mori H, Kawamura N, Matsuura M, Hisamatsu T. Ratio of submucosal thickness to total bowel wall thickness as a new sonographic parameter to estimate endoscopic remission of ulcerative colitis. J Gastroenterol. 2022;57(2):82-89.
Miyoshi J, Matsuura M, Hisamatsu T. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. Expert Opin Drug Saf. 2022;21(1):1-8.
Miura M, Shimizu H, Saito D, Miyoshi J, Matsuura M, Kudo T, Hirayama D, Yoshida M, Arai K, Iwama I, Nakase H, Shimizu T, Hisamatsu T. Multicenter, cross-sectional, observational study on Epstein-Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan (EBISU study). J Gastroenterol. 2021;56(12):1080-1091.
Miyoshi J, Miyoshi S, Delmont TO, Cham C, Lee STM, Sakatani A, Yang K, Shan Y, Kennedy M, Kiefl E, Yousef M, Crosson S, Sogin M, Antonopoulos DA, Eren AM, Leone V, Chang EB. Early-Life Microbial Restitution Reduces Colitis Risk Promoted by Antibiotic-Induced Gut Dysbiosis in Interleukin 10-/- Mice. Gastroenterology. 2021;161(3):940-952.e15.
Miyoshi J, Lee STM, Kennedy M, Puertolas M, Frith M, Koval JC, Miyoshi S, Antonopoulos DA, Leone V, Chang EB. Metagenomic Alterations in Gut Microbiota Precede and Predict Onset of Colitis in the IL10 Gene-Deficient Murine Model. Cell Mol Gastroenterol Hepatol. 2021;11(2):491-502.
Sakuraba A, Nemoto N, Hibi N, Ozaki R, Tokunaga S, Kikuchi O, Minowa S, Mitsui T, Miura M, Saito D, Hayashida M, Miyoshi J, Matsuura M, Yoneyama M, Ohnishi H, Hisamatsu T. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis. BMC Gastroenterol. 2021;21(1):197.
Watanabe S, Miyoshi J*, Toki M, Kambayashi K, Kitada S, Nosaka T, Goto T, Ota H, Ochiai K, Gondo K, Ikeuchi N, Tsuji S, Nakamura K, Shibahara J, Hisamatsu T. Effectiveness of introducing a 20-gauge core biopsy needle with a core trap in EUS-FNA/B for diagnosing pancreatic cancer. BMC Gastroenterol. 2021;21(1):8. *co-corresponding author
Miyoshi J, Maeda T, Matsuoka K, Saito D, Miyoshi S, Matsuura M, Okamoto S, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis. Sci Rep. 2021;11(1):16440.
Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, Miura M, Sakuraba A, Hayashida M, Miyoshi J, Hisamatsu T. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open. 2021;5(9):1056-1062.
Miyoshi J, Hisamatsu T. The impact of maternal exposure to antibiotics on the development of child gut microbiome. Immunol Med. 2021. doi: 10.1080/25785826.2021.1963189. Epub ahead of print.
Miyoshi J, Rao MC, Chang EB. Navigating the Human Gut Microbiome: Pathway to Success from Lessons Learned. Gastroenterology. 2020;159(6):2019-2024.
Ohno A, Miyoshi J, Tanabe H, Kusuhara M, Toki M, Chiba T, Shimoyamada H, Shibahara J, Hisamatsu T. Gastropathy associated with lanthanum phosphate deposition that was endoscopically tracked for 3 years. A case report. BMC Gastroenterol. 2020;20(1):292.
Miyoshi J, Lee STM, Kennedy M, Puertolas M, Frith M, Koval JC, Miyoshi S, Antonopoulos DA, Leone V, Chang EB. Metagenomic Alterations in Gut Microbiota Precede and Predict Onset of Colitis in the IL10 Gene-Deficient Murine Model. Cell Mol Gastroenterol Hepatol. 2020:S2352-345X(20)30132-6.
Miyoshi J, Saito D, Nakamura M, Miura M, Mitsui T, Kudo T, Murakami S, Matsuura M, Hisamatsu T. Half-Elemental Diet Shifts the Human Intestinal Bacterial Compositions and Metabolites: A Pilot Study with Healthy Individuals. Gastroenterol Res Pract. 2020;2020:7086939.
Ohno A, Miyoshi J*, Kato A, Miyamoto N, Yatagai T, Hada Y, Kusuhara M, Jimbo Y, Ida Y, Tokunaga K, Okamoto S, Hisamatsu T. Endoscopic severe mucosal atrophy indicates the presence of gastric cancer after Helicobacter pylori eradication -analysis based on the Kyoto classification. BMC Gastroenterol. 2020;20(1):232. *co-corresponding author
Kikuchi O, Saito D, Miura M, Wada H, Ozaki R, Tokunaga S, Minowa S, Fukuyama M, Mitsui T, Sakuraba A, Hayashida M, Miyoshi J, Matsuura M, Ohyama M, Hisamatsu T. Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata. Clin J Gastroenterol. 2020;13(5):788-793.
Basson AR, LaSalla A, Lam G, Kulpins D, Moen EL, Sundrud MS, Miyoshi J, Ilic S, Theriault BR, Cominelli F, Rodriguez-Palacios A. Artificial microbiome heterogeneity spurs six practical action themes and examples to increase study power-driven reproducibility. Sci Rep. 2020;10(1):5039.
Hayashida M, Miyoshi J*, Mitsui T, Miura M, Saito D, Sakuraba A, Kawashima S, Ikegaya N, Fukuoka K, Karube M, Komagata Y, Kaname S, Okada AA, Fujimori S, Matsuura M, Hisamatsu T. Elevated fecal calprotectin and lactoferrin associated with small intestinal lesions in patients With Behçet disease. J Gastroenterol Hepatol. 2020; 35(8):1340-1346. *co-corresponding author
Saito D, Hibi N, Ozaki R, Kikuchi O, Sato T, Tokunaga S, Minowa S, Ikezaki O, Mitsui T, Miura M, Sakuraba A, Hayashida M, Miyoshi J, Matsuura M, Nakase H, Hisamatsu T. MEFV gene-related enterocolitis account for some cases diagnosed as inflammatory bowel disease unclassified. Digestion. 2020;101(6):785-793.
Miyoshi J, Sofia MA, Pierre JF. The evidence for fungus in Crohn's disease pathogenesis. Clin J Gastroenterol. 2018; 11(6):449-456.
Miyoshi J, Matsuoka K, Yoshida A, Naganuma M, Hisamatsu T, Yajima T, Inoue N, Okamoto S, Iwao Y, Ogata H, Ueno F, Hibi T, Kanai T. 5-aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis. Intest Res. 2018;16(4):635-640.
Miyoshi J, Leone V, Nobutani K, Musch MW, Martinez-Guryn K, Wang Y, Miyoshi S, Bobe AM, Eren AM, Chang EB. Minimizing confounders and increasing data quality in murine models for studies of the gut microbiome. PeerJ. 2018;6:e5166.
Martinez-Guryn K, Hubert N, Frazier K, Urlass S, Musch MW, Ojeda P, Pierre JF, Miyoshi J, Sontag TJ, Cham CM, Reardon CA, Leone V, Chang EB. Small intestine microbiota regulate host digestive and absorptive adaptive responses to dietary lipids. Cell Host Microbe. 2018;23(4):458-469.e5.
Pierre JF, Hinterleitner R, Bouziat R, Hubert NA, Leone V, Miyoshi J, Jabri B, Chang EB. Dietary antioxidant micronutrients alter mucosal inflammatory risk in a murine model of genetic and microbial susceptibility. J Nutr Biochem. 2018;54:95-104.
Miyoshi J, Qiao Y, Chang EB. The role of the intestinal microbiota in the pathogenesis and treatment of inflammatory bowel diseases. Semin Colon Rectal Surg 2018;29:21-27.
Miyoshi J, Nobutani K, Musch MW, Ringus DL, Hubert NA, Yamamoto M, Kase Y, Nishiyama M, Chang EB. Time-, Sex-, and Dose-Dependent Alterations of the Gut Microbiota by Consumption of Dietary Daikenchuto (TU-100). Evid Based Complement Alternat Med. 2018;2018:7415975.
Nobutani K, Miyoshi J, Musch MW, Nishiyama M, Watanabe J, Kaneko A, Yamamoto M, Yoshida M, Kono T, Jeong H, Chang EB. Daikenchuto (TU-100) alters murine hepatic and intestinal drug metabolizing enzymes in an in vivo dietary model: effects of gender and withdrawal. Pharmacol Res Perspect. 2017;5(5):e00361.
Miyoshi J, Bobe AM, Miyoshi S, Huang Y, Hubert N, Delmont TO, Eren AM, Leone V, Chang EB. Peripartum antibiotics promote gut dysbiosis, loss of immune tolerance, and inflammatory bowel disease in genetically prone offspring. Cell Rep. 2017;20(2):491-504.
Hasebe T, Matsukawa J, Ringus D, Miyoshi J, Hart J, Kaneko A, Yamamoto M, Kono T, Fujiya M, Kohgo Y, Wang CZ, Yuan CS, Bissonnette M, Musch MW, Chang EB. Daikenchuto (TU-100) suppresses tumor development in the azoxymethane and APCmin/+ mouse models of experimental colon cancer. Phytother Res. 2017;31(1):90-99.
Miyoshi J, Chang EB. The gut microbiota and inflammatory bowel diseases. Transl Res. 2017;179:38-48.

(公的研究助成金など)
2022年 武田薬品ジャパンメディカルオフィス研究助成
2021年 杏林大学共同研究プロジェクト
2020年 科学研究費(基盤研究C)
2020年 ECCO-AOCC Visiting Travel Grant
2019年 応用酵素協会若手研究助成
2019年 科学研究費(研究活動スタート支援)
2019年 杏林大学医学部若手支援研究費
2017年 Gastrointestinal Research Foundation Research Funding
所属学会日本内科学会
日本消化器病学会(関東支部評議員)
日本消化器内視鏡学会
日本消化管学会
日本消化器免疫学会(評議員)
日本炎症性腸疾患学会
日本臨床免疫学会
日本大腸肛門病学会
日本臨床腫瘍学会
Asian Organization for Crohn’s & Colitis
European Crohn's and Colitis Organisation
American Gastroenterological Association
関連サイト 杏林大学医学部消化器内科学

TEST